TY - JOUR
T1 - The Chilean COVID-19 Genomics Network Biorepository
T2 - A Resource for Multi-Omics Studies of COVID-19 and Long COVID in a Latin American Population
AU - Signore, Iskra A.
AU - Donoso, Gerardo
AU - Bocchieri, Pamela
AU - Tobar-Calfucoy, Eduardo A.
AU - Yáñez, Cristian E.
AU - Carvajal-Silva, Laura
AU - Silva, Andrea X.
AU - Otth, Carola
AU - Cappelli, Claudio
AU - Valenzuela Jorquera, Héctor
AU - Zapata-Contreras, Daniela
AU - Espinosa-Parrilla, Yolanda
AU - Zúñiga-Pacheco, Paula
AU - Fuentes-Guajardo, Macarena
AU - Monardes-Ramírez, Virginia A.
AU - Kochifas Velasquez, Pia
AU - Muñoz, Christian A.
AU - Dorador, Cristina
AU - García-Araya, Jonathan
AU - Campillay-Véliz, Claudia P.
AU - Echeverria, Cesar
AU - Santander, Rodolfo Alejandro
AU - Cerpa, Leslie C.
AU - Martínez, Matías F.
AU - Quiñones, Luis Abel
AU - Lamoza Galleguillos, Eduardo Roberto
AU - Saez Hidalgo, Juan
AU - Nova-Lamperti, Estefanía
AU - Sanhueza, Sergio
AU - Giacaman, Annesi
AU - Acosta-Jamett, Gerardo
AU - Verdugo, Cristóbal
AU - Plaza, Anita
AU - Verdugo, Claudio
AU - Selman, Carolina
AU - Verdugo, Ricardo Alejandro
AU - Colombo, Alicia
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/11
Y1 - 2024/11
N2 - Although a lack of diversity in genetic studies is an acknowledged obstacle for personalized medicine and precision public health, Latin American populations remain particularly understudied despite their heterogeneity and mixed ancestry. This gap extends to COVID-19 despite its variability in susceptibility and clinical course, where ethnic background appears to influence disease severity, with non-Europeans facing higher hospitalization rates. In addition, access to high-quality samples and data is a critical issue for personalized and precision medicine, and it has become clear that the solution lies in biobanks. The creation of the Chilean COVID-19 Biorepository reported here addresses these gaps, representing the first nationwide multicentric Chilean initiative. It operates under rigorous biobanking standards and serves as one of South America’s largest COVID cohorts. A centralized harmonization strategy was chosen and included unified standard operating procedures, a sampling coding system, and biobanking staff training. Adults with confirmed SARS-CoV-2 infection provided broad informed consent. Samples were collected to preserve blood, plasma, buffy coat, and DNA. Quality controls included adherence to the standard preanalytical code, incident reporting, and DNA concentration and absorbance ratio 260/280 assessments. Detailed sociodemographic, health, medication, and preexisting condition data were gathered. In five months, 2262 participants were enrolled, pseudonymized, and sorted by disease severity. The average Amerindian ancestry considering all participant was 44.0% [SD 15.5%], and this value increased to 61.2% [SD 19.5%] among those who self-identified as Native South Americans. Notably, 279 participants self-identified with one of 12 ethnic groups. High compliance (>90%) in all assessed quality controls was achieved. Looking ahead, our team founded the COVID-19 Genomics Network (C19-GenoNet) focused on identifying genetic factors influencing SARS-CoV-2 outcomes. In conclusion, this bottom-up collaborative effort aims to promote the integration of Latin American populations into global genetic research and welcomes collaborations supporting this endeavor. Interested parties are invited to explore collaboration opportunities through our catalog, accessible online.
AB - Although a lack of diversity in genetic studies is an acknowledged obstacle for personalized medicine and precision public health, Latin American populations remain particularly understudied despite their heterogeneity and mixed ancestry. This gap extends to COVID-19 despite its variability in susceptibility and clinical course, where ethnic background appears to influence disease severity, with non-Europeans facing higher hospitalization rates. In addition, access to high-quality samples and data is a critical issue for personalized and precision medicine, and it has become clear that the solution lies in biobanks. The creation of the Chilean COVID-19 Biorepository reported here addresses these gaps, representing the first nationwide multicentric Chilean initiative. It operates under rigorous biobanking standards and serves as one of South America’s largest COVID cohorts. A centralized harmonization strategy was chosen and included unified standard operating procedures, a sampling coding system, and biobanking staff training. Adults with confirmed SARS-CoV-2 infection provided broad informed consent. Samples were collected to preserve blood, plasma, buffy coat, and DNA. Quality controls included adherence to the standard preanalytical code, incident reporting, and DNA concentration and absorbance ratio 260/280 assessments. Detailed sociodemographic, health, medication, and preexisting condition data were gathered. In five months, 2262 participants were enrolled, pseudonymized, and sorted by disease severity. The average Amerindian ancestry considering all participant was 44.0% [SD 15.5%], and this value increased to 61.2% [SD 19.5%] among those who self-identified as Native South Americans. Notably, 279 participants self-identified with one of 12 ethnic groups. High compliance (>90%) in all assessed quality controls was achieved. Looking ahead, our team founded the COVID-19 Genomics Network (C19-GenoNet) focused on identifying genetic factors influencing SARS-CoV-2 outcomes. In conclusion, this bottom-up collaborative effort aims to promote the integration of Latin American populations into global genetic research and welcomes collaborations supporting this endeavor. Interested parties are invited to explore collaboration opportunities through our catalog, accessible online.
KW - biobank networks
KW - biorepository
KW - COVID-19
KW - genetic diversity
KW - Latin American populations
KW - underrepresented populations
UR - http://www.scopus.com/inward/record.url?scp=85210246546&partnerID=8YFLogxK
U2 - 10.3390/genes15111352
DO - 10.3390/genes15111352
M3 - Article
C2 - 39596552
AN - SCOPUS:85210246546
SN - 2073-4425
VL - 15
JO - Genes
JF - Genes
IS - 11
M1 - 1352
ER -